Chongqing Zhengchuan Pharmaceutical Packaging Co. Ltd. Class A

Chongqing Zhengchuan Pharmaceutical Packaging Co. Ltd. Class A

SSSE:603976
28.02
CNY
0.00
(0.00%)
0.13EPS
219.88P/E
5.08BMarket Cap
Chongqing Zhengchuan Pharmaceutical Packaging Co. Ltd. Class A
SSE:603976
(Shanghai Stock Exchange)

Recent

price

28.02

P/E

ratio

219.88

div

yld

0.00%

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
3.6
3.84
4.23
4.14
4.02
3.96
3.41
3.31
5.31
5.29
6.04
5.27
4.57
4.92
Revenue per Share
0.49
0.61
0.54
0.62
0.65
0.55
0.4
0.35
0.71
0.43
0.27
0.35
0.13
0.13
Basic EPS, GAAP
- -
0.51
0.04
0.15
0.12
-0.03
-0.37
-0.36
-0.22
-1.58
0.7
0.26
0.75
- -
Free Cash Flow per Basic Share
0.03
0.26
0.3
0.16
0.03
0.33
0.08
0.33
0.04
0.33
0.09
0.33
0.31
- -
Dividend per Share
4.78
5.24
4.06
4.54
6.31
6.53
6.85
6.88
7.71
7.83
8.04
8.09
7.97
9.48
Book Value per Share
4.64
5.11
3.97
4.27
6.11
6.24
6.57
6.6
7.43
7.56
7.77
7.83
7.72
9.26
Tangible Book Value per Share
113
114
113
113
126
150
153
152
150
151
149
152
145
153
Basic Weighted Avg Shares
406
436
480
470
509
596
521
502
797
796
901
801
664
752
Sales/Revenue/Turnover
14.96
17.25
14.38
17.38
18.73
14.28
11.48
10.47
16.17
10.71
6.58
11.75
7.25
7.05
Operating Margin (%)
- -
25
27
32
42
48
51
53
67
86
106
115
107
- -
Depreciation Expense
55
69
61
71
82
83
61
53
107
65
40
53
19
21
Net Income, GAAP
13.07
13.65
12.81
15.11
15.24
11.96
14.42
13.57
15.38
- -
10.17
11.56
5.68
19.99
Effective Tax Rate (%)
13.49
15.8
12.65
15
16.16
13.89
11.72
10.57
13.38
8.13
4.47
6.65
2.85
2.74
Profit Margin (%)
239
266
221
206
616
600
559
386
773
602
672
606
838
669
Working Capital
- -
- -
- -
- -
- -
- -
- -
1
383
400
416
432
446
14
LT Debt
401
440
461
515
954
987
1,036
1,040
1,166
1,184
1,216
1,223
1,205
1,627
Total Equity
- -
15.57
13.05
13.53
11.09
8.56
6.1
5.05
7.7
- -
2.45
3.5
1.19
1.25
Return on Invested Capital (%)
- -
16.54
13.52
14.32
11.14
8.53
6.04
5.01
8.74
- -
3.59
4.33
2.36
2.11
Return on Capital (%)
- -
16.39
13.48
14.45
11.19
8.53
6.04
5.11
9.66
5.51
3.36
4.37
1.56
1.46
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
3
3
LT Borrowings
451
440
14
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
151
152
172
Market Capitalization
3,027
4,384
5,078

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,120
894
904
Cash, Cash Equivalents & STI
357
319
370
Accounts Receivable, Net
228
200
172
Inventories
192
194
195
Total Current Liabilities
257
256
235
Payables & Accruals
- -
- -
- -
ST Debt
- -
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.13%
3.09%
-1.49%
Free Cash Flow
172.28%
111.3%
172.09%
Net Income, GAAP
-1.43%
-1.68%
-64.5%
Sales/Revenue/Turnover
5.08%
8.73%
-17.07%
Total Cash Common Dividend
203.41%
161.66%
-12.22%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
246
215
149
191
801
2025
162
162
- -
207
664
2026
209
172
165
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.15
0.05
0.01
0.35
2025
0.07
0.02
- -
0.02
0.13
2026
0.05
0.04
0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.23
0.1
- -
0.33
2025
- -
- -
- -
- -
0.31
2026
- -
- -
- -
- -
- -
Business
ChongQing Zhengchuan Pharmaceutical Packaging Co.,Ltd (603976.SS) is a China-based company principally engaged in the research, development, production and sale of pharmaceutical primary packaging materials, primarily tubular glass vials, ampoules and auxiliary caps; it operates four production bases with over 2,000 employees and annual capacity exceeding 10 billion glass vials, 1 billion ampoules, 1 billion cartridges, 50 million prefilled syringes and 5 billion aluminum caps. The company offers neutral borosilicate glass tubular injection vials (2ml to 50ml), low borosilicate tubular vials and ampoules, oral liquid vials, screw-neck vials, prefilled syringes (1ml to 3ml with needle or luer lock), ready-to-use cartridges (1.5ml to 3ml), push rods and injection boosters for prefilled syringes; it also provides aluminum caps, aluminum-plastic composite caps and other medicinal closures, all compliant with YBB, ISO, EP, USP standards, ISO15378, ISO17025 and US FDA DMF certifications. Products serve biological preparations, traditional Chinese medicine, chemical medicines including water/powder injections and oral liquids, plus health care products; operations span China with exports to markets including India, United States, Brazil, Vietnam, Russia, Japan, Germany and others. Founded in 1988 and headquartered in Zhengchuan Glass Industry Park, Longfengqiao Street, Beibei District, Chongqing, China, the company listed on the Shanghai Stock Exchange main board in 2017 as the first private enterprise in the pharmaceutical glass packaging sector; it maintains partnerships with leading suppliers such as Schott, NEG, Aptar and Datwyler. Recent developments include the ignition and operation of its second medium borosilicate kiln in July 2022, expansion of neutral borosilicate glass production projects funded by capital raises, attendance at CPHI China 2024 (booth N5B10) and CPHI Shanghai 2025 to showcase aseptic packaging solutions, alongside ongoing investments in borosilicate pharmaceutical glass amid national centralized procurement driving medium borosilicate adoption.